← Back to Treatments
🏅 FDA Orphan Designation

Velcade

bortezomib

Manufacturer: Takeda Pharmaceuticals U.S.A., Inc.

Indicated for:
Multiple myelomaOrphanMantle cell lymphoma

FDA-Approved Indications (2)

Multiple myelomaOrphan Designation

Treatment of multiple myeloma patients who have received at least one prior therapy

VELCADE is indicated for the treatment of adult patients with mantle cell lymphoma

Population: adults

Indications & Usage

1 INDICATIONS AND USAGE VELCADE is a proteasome inhibitor indicated for: treatment of adult patients with multiple myeloma ( 1.1 ) treatment of adult patients with mantle cell lymphoma ( 1.2 ) 1.1 Multiple Myeloma VELCADE is indicated for the treatment of adult patients with multiple myeloma. 1.2 Mantle Cell Lymphoma VELCADE is indicated for the treatment of adult patients with mantle cell lymphoma.

💙 Support Programs

View all →
Bortezomib
Takeda
Copay card ↗Apply ↗
VELCADE
Takeda
Copay card ↗Apply ↗

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.